Global pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN, LON: AZN) has reported updated results from the Phase III LAURA study on its EGFR-tyrosine kinase inhibitor (EGFR-TKI), Tagrisso (osimertinib), at the 2024 European Society of Medical Oncology (ESMO) Congress. The study included data from the Chinese cohort, highlighting the drug’s efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC).
The LAURA trial, a double-blinded, randomized-controlled, multi-center Phase III study, enrolled 216 patients with EGFR mutant stage III unresectable NSCLC who did not progress after radical radiotherapy and chemotherapy. Patients were allocated in a 2:1 ratio to receive either osimertinib or a placebo for consolidation treatment. The study had previously reported a median progression-free survival (PFS) of 39.1 months for the osimertinib group versus 5.6 months for the placebo group at the 2024 ASCO annual meeting.
The latest ESMO data showed that osimertinib reduced the risk of central nervous system (CNS) disease or death by 83% and significantly improved the median time to distant metastasis (TTDM) with a HR of 0.21 (P<0.001). Among the Chinese patients, the PFS rates at 12 and 24 months were 80% and 71% for the osimertinib group, compared to 17% and 8% for the placebo group, respectively. These results reinforce the potential of osimertinib as a maintenance treatment for patients with EGFR-mutated stage III non-resectable NSCLC post-radical chemotherapy and radiotherapy.-Fineline Info & Tech
